全文获取类型
收费全文 | 1004121篇 |
免费 | 75614篇 |
国内免费 | 6219篇 |
专业分类
耳鼻咽喉 | 13529篇 |
儿科学 | 25601篇 |
妇产科学 | 23904篇 |
基础医学 | 139447篇 |
口腔科学 | 29746篇 |
临床医学 | 89567篇 |
内科学 | 192473篇 |
皮肤病学 | 19983篇 |
神经病学 | 75557篇 |
特种医学 | 39882篇 |
外国民族医学 | 106篇 |
外科学 | 159382篇 |
综合类 | 33850篇 |
现状与发展 | 14篇 |
一般理论 | 236篇 |
预防医学 | 68139篇 |
眼科学 | 23287篇 |
药学 | 80673篇 |
56篇 | |
中国医学 | 7913篇 |
肿瘤学 | 62609篇 |
出版年
2021年 | 9242篇 |
2019年 | 8243篇 |
2018年 | 11336篇 |
2017年 | 9530篇 |
2016年 | 10014篇 |
2015年 | 12162篇 |
2014年 | 16197篇 |
2013年 | 22018篇 |
2012年 | 30397篇 |
2011年 | 31558篇 |
2010年 | 19881篇 |
2009年 | 18592篇 |
2008年 | 29357篇 |
2007年 | 30284篇 |
2006年 | 30848篇 |
2005年 | 29054篇 |
2004年 | 27493篇 |
2003年 | 26276篇 |
2002年 | 25267篇 |
2001年 | 56404篇 |
2000年 | 57786篇 |
1999年 | 47874篇 |
1998年 | 11231篇 |
1997年 | 10021篇 |
1996年 | 9986篇 |
1995年 | 9252篇 |
1994年 | 8578篇 |
1993年 | 7775篇 |
1992年 | 35625篇 |
1991年 | 34040篇 |
1990年 | 32848篇 |
1989年 | 31953篇 |
1988年 | 29071篇 |
1987年 | 28316篇 |
1986年 | 26342篇 |
1985年 | 25170篇 |
1984年 | 17850篇 |
1983年 | 15159篇 |
1982年 | 7802篇 |
1979年 | 15784篇 |
1978年 | 10600篇 |
1977年 | 9052篇 |
1976年 | 7873篇 |
1975年 | 8629篇 |
1974年 | 10468篇 |
1973年 | 9858篇 |
1972年 | 9357篇 |
1971年 | 8852篇 |
1970年 | 8428篇 |
1969年 | 7923篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
52.
53.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
54.
55.
56.
An-feng TAO Zheng-hao XU Cheng-hao WU Yi WANG Wei-wei HOU Shi-hong ZHANG Zhong CHEN 《浙江大学学报(医学版)》2015,44(3):315
目的观察比较不同脉冲波形的低频率电刺激对海马电点燃癫痫模型小鼠的作用差异。方法采用电点燃刺激法建立小鼠癫痫模型, 观察正弦波、单相方波、双相方波低频率电刺激对模型小鼠癫痫行为发作及后放电持续时间的影响, 并比较不同时间点给予正弦波低频率电刺激的抗癫痫作用。结果与对照组比较, 正弦波低频率电刺激30 s能降低小鼠海马电点燃癫痫发作等级(2.85 ± 0.27 vs 4.75 ±0.12, P < 0.05)、减少大发作概率(53.6% vs 96.5%, P < 0.01) 和缩短后放电持续时间[(16.22 ± 1.69) s vs (30.29 ± 1.12) s, P < 0.01], 而单相方波和双相方波低频率电刺激30 s没有明显的抗癫痫作用。常用的单相方波低频率电刺激15 min能降低小鼠海马电点燃发作等级(3.58 ± 0.16, P < 0.05)、减少大发作概率(66.7%, P < 0.01);但对海马后放电持续时间及大发作持续时间无影响(均 P>0.05)。此外, 电点燃刺激前预先给予或结束后3 s内给予正弦波低频率电刺激具有明显的抗癫痫作用( P < 0.05或 P < 0.01), 而电点燃刺激结束10 s给予正弦波低频率电刺激则无上述抗癫痫作用。 结论低频率电刺激抗癫痫作用受波形参数的影响, 其中正弦波低频率电刺激能有效抑制小鼠海马电点燃癫痫的发作。 相似文献
57.
58.
59.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
60.